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Abstract 
Purpose: The aim of the study was to define the frequency of hereditary forms and the 
genotype/phenotype correlations in a large cohort of Italian patients with pheochromocytomas 
and/or functional or nonfunctional paragangliomas. 
Design: We examined 501 consecutive patients with pheochromocytomas and/or paragangliomas 
(secreting or nonsecreting). Complete medical and family histories, as well as the results of clinical, 
laboratory, and imaging studies, were recorded in a database. Patients were divided into different 
groups according to their family history, the presence of lesions outside adrenals/paraganglia 
considered syndromic for VHL disease, MEN2, and NF1, and the number and types of 
pheochromocytomas and/or paragangliomas. Germ-line mutations in known susceptibility genes 
were investigated by gene sequencing (VHL, RET, SDHB, SDHC, SDHD) or diagnosed according 
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to phenotype (NF1). In 160 patients younger than 50 yr with a wild-type profile, multiplex ligation-
dependent probe amplification assays were performed to detect genomic rearrangements. 
Results: Germline mutations were detected in 32.1% of cases, but frequencies varied widely 
depending on the classification criteria and ranged from 100% in patients with associated 
syndromic lesions to 11.6% in patients with a single tumor and a negative family history. The types 
and number of pheochromocytomas/paragangliomas as well as age at presentation and malignancy 
suggest which gene should be screened first. Genomic rearrangements were found in two of 160 
patients (1.2%). 
Conclusions: The frequency of the hereditary forms of pheochromocytoma/paraganglioma varies 
depending on the family history and the clinical presentation. A positive family history and an 
accurate clinical evaluation of patients are strong indicators of which genes should be screened first. 
Family history and clinical evaluation are important clues in directing genetic analysis in patients 
with pheochromocytomas and/or paragangliomas. 
Pheochromocytomas (Pheos) and paragangliomas (PGLs) are neural crest-derived tumors. The 
former are found in the adrenals, develop from chromaffin cells, and generally secrete 
catecholamines. Chromaffin tumors, located outside the adrenals, in the abdomen and the thorax, 
are named PGLs. In the present manuscript these tumors will be referred to as “secreting PGLs” 
(sPGLs) to distinguish them from PGLs of the head and neck (HNPGLs), which are 
parasympathetic in origin and, for the vast majority, nonsecreting. 
Susceptibility to Pheos and PGLs is an established component of three genetic syndromes, von 
Hippel-Lindau (VHL) disease, multiple endocrine neoplasia type 2 (MEN2), and neurofibromatosis 
type 1 (NF1), which are caused, respectively, by germ-line mutations of the tumor-suppressor gene 
VHL, the protooncogene RET, and the NF-1 gene, which also functions as a tumor suppressor (1, 2). 
These syndromes are characterized, in addition to Pheo/PGL, by lesions involving organs other than 
the adrenals or the paraganglia. These lesions will be referred to as “syndromic.” More recent work 
has highlighted the importance of SDHB, SDHC, and SDHD genes that encode the B, C, and D 
subunits of succinate dehydrogenase (SDH), also known as mitochondrial complex II (3, 4, 5). 
Mutations of the SDHB, SDHC, and SDHD genes are associated with three clinical syndromes 
referred to as PGL4, PGL3, and PGL1, respectively. These syndromes are mostly characterized by 
HNPGLs variably associated with Pheo/sPGL. At present, no other lesions have been identified as 
typical components of these syndromes. 
Hereditary forms were once believed to represent around 10% of all Pheos/PGLs, but in 2002, 
Neumann et al. (6) reported germ-line mutations involving four known susceptibility genes in 66 
(24%) of 271German/Polish patients with clinical findings suggestive of sporadic tumors. This 
report led to the recommendation that all patients with Pheo/sPGL be screened for hereditary 
disease. However, the cost implications of this proposal are considerable, and the reasoning that 
supports it must be critically analyzed before such a policy is adopted (7, 8). Systematic mutation 
analysis of all of the currently known susceptibility genes is considerably expensive, and some type 
of clinical prescreening is recommended to identify the most likely target of the mutation. 
Nevertheless, selection of patients with Pheo/PGL for genetic testing is a complex process. 
Family history can be of some help in identifying a hereditary form. A positive history may be 
highly informative (e.g. a relative with an already established diagnosis or lesions typical of 
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syndromic disease) or partially informative (a relative with a single Pheo/PGL). The clinical 
presentation can also provide useful clues, but any decision must rely on a thorough knowledge of 
the possible genes involved, their characteristics (mode of transmission, penetrance), and especially 
the correlated clinical pictures. Unfortunately, these latter may be extremely variable; whereas some 
patients present associated syndromic lesions that are diagnostic for VHL, MEN2, and NF1, in 
others, when these syndromic lesions are absent, only the number, type, and association of Pheos, 
sPGLs, or HNPGLs has to be considered. In the presence of only one Pheo/PGL, only a positive 
family history suggests a hereditary form, whereas the presence of multiple or recurrent Pheos/PGL 
strongly suggests a genetic form that has to be further defined by the genetic analysis. In fact, 
different syndromes can sometimes share a common clinical picture as, for example, 
bilateral/recurrent Pheos in VHL or MEN2 and association of HNPGLs with sPGL in PGL4 or 
PGL1. 
The Pheochromocytoma/Paraganglioma Working Group of the Italian Society of Endocrinology 
recently performed genetic testing in a large cohort of Italian patients with secreting and/or 
nonsecreting PGLs. Our objective was to characterize the frequency and distribution of genetically 
determined Pheos and PGLs in this geographic area and to identify phenotypic clues that can be 
used to guide decisions on the use of genetic testing in patients with these tumors. 
Patients and Methods 
The study protocol was preapproved by the institutional review boards of all participating centers, 
and each participant provided written informed consent to all study procedures (including genetic 
testing) and to publication of the results. Unless otherwise stated, all commercial products 
mentioned below were used according to manufacturers’ instructions. 
Patients 
The study population consisted of 501 consecutive patients (adults and children) with Pheo and/or 
PGLs visited in the 17 endocrinology or hypertension centers of the Italian 
Pheochromocytoma/Paraganglioma Network between January 1, 2003, and December 30, 2007. 
The only inclusion criterion was a past or new diagnosis of Pheo or PGL. Upon enrollment, each 
participant was evaluated according to a well-established protocol that included complete personal 
and family histories, clinical evaluation, and a panel of laboratory tests and imaging studies aimed 
at detecting lesions considered diagnostic for VHL, MEN2, and NF1 (syndromic lesions). 
Diagnoses of Pheo or sPGL were based on plasma or urinary levels of catecholamines or 
catecholamine metabolites (mainly metanephrines) and confirmed by iodine
123
-labeled 
metaiodobenzylguanidine scintigraphy and/or surgical histology. HNPGLs were diagnosed on the 
basis of imaging findings (presence in the region of a highly vascular mass on computed 
tomography, magnetic resonance imaging, ultrasonography, or somatostatin receptor scintigraphy 
with indium
111
-labeled pentetreotide, as appropriate) and, when possible, surgical histology. 
Malignancy was defined as the presence of metastases outside the paraganglia or adrenals (mostly 
in bones, lungs, and liver). 
On the basis of the results of this workup, participants were classified according to their family 
history (positive/negative), the presence/absence of syndromic lesions, and the number and type of 
Pheo/PGL. 
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Mutation analysis 
With the exception of NF1 mutations, which were diagnosed on the basis of phenotype alone as 
generally accepted (9, 10), all germ-line mutations were documented by the results of genetic 
testing performed according to standardized protocols in the centers of Florence, Brescia, Padua, or 
Rome. DNA was extracted from the peripheral blood leukocytes of each patient with the 
NucleoSpin Blood L kit (Macherey-Nagel, Düren, Germany) and analyzed for germ-line mutations 
of RET (exons 10, 11, 13, 14, 15, and 16), VHL (all exons), SDHD (all exons), SDHB (all exons), 
and SDHC (all exons). For each gene, coding regions and exon-intron boundaries were amplified by 
PCR as previously described (11). PCR products purified with a commercial kit (PCR purification 
kit; QIAGEN, Milan, Italy) were subjected to 2% agarose gel electrophoresis with ethidium 
bromide staining and subsequently sequenced with a genetic analyzer (ABI PRISM 310; Applied 
Biosystems, Milan, Italy). 
Multiplex ligation-dependent probe amplification reactions 
A total of 160 patients under 50 yr of age whose DNA sequencing results revealed wild-type RET, 
VHL, SDHB, SDHC, and SDHD were subsequently analyzed for genomic rearrangements involving 
the VHL or one of the SDH genes. For this purpose, we used commercial kits for multiplex ligation-
dependent probe amplification (MLPA)-based assays (SALSA MLPA P016B VHL and SALSA 
MLPA P226 SDHD; MRC-Holland, Amsterdam, The Netherlands) following the manufacturer’s 
instructions. 
The PCR was carried out as follows: 35 cycles of 30 sec at 95 C; 30 sec at 60 C; 60 sec at 72 C; and 
20 min of final incubation at 72 C. Amplification products were diluted in HiDi formamide 
containing 500TAMRA internal size standards (Applied Biosystems, Foster City, CA) and then 
size-separated with an ABI PRISM 310 Genetic Analyser (Applied Biosystems, Milan, Italy). 
Electropherograms were analyzed with Coffalyser MLPA DAT software (MRC-Holland). 
Statistical analysis 
Statistical analysis was based on χ2 test, and P values <0.05 were considered statistically 
significant. 
Results 
Overall, 501 patients were enrolled in the study (288 females and 213 males; mean age, 44.7 yr; age 
range, 5–93 yr). 
Table 1 summarizes the characteristics of the patient groups defined on the basis of family histories 
and clinical presentations. 
Fifty-seven patients had a positive family history. Among these, 16 presented, in addition to 
Pheo/PGL, with at least one syndromic lesion, 27 presented with multiple or recurrent Pheos/PGLs 
without any other known syndromic lesion, and 14 presented with only a single Pheo, sPGL, or 
HNPGL. Germline mutations were found in 100.0, 100.0, and 64.3% of cases, respectively. 
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Among the 444 patients with a negative family history, 50 presented with at least one syndromic 
lesion, 49 with multiple or recurrent Pheo/PGL, and 345 with a single Pheo, sPGL, or HNPGL. The 
germ-line mutation rates in these three subgroups were 100.0, 38.8, and 11.6%, respectively. 
On the whole, 91.2% of the patients with a positive family history and 24.5% of those with a 
negative family history were mutation carriers. A total of 161 (32.1%) of 501 patients harbored 
germ-line mutations involving VHL (48 patients, 9.6%), RET (27 patients, 5.3%), NF1 (as deduced 
from the phenotype, 11 patients, 2.2%), SDHB (24 patients, 4.7%), SDHC (4 patients, 0.8%), or 
SDHD (47 patients, 9.4%). 
Within the group of 345 patients with a single tumor and negative family history (those most likely 
to have truly sporadic disease), the subgroup with Pheos/sPGLs and the one with HNPGLs had 
similar germ-line mutation rates (10.8 and 14.3%, respectively). However, the former subgroup was 
characterized by lower ages at presentation, with a peak frequency in the second decade vs. third 
decade for HNPGLs (Fig. 1). 
Eighty-two percent of germ-line mutations (132 of 161) were found in patients younger than 50 yr. 
In older patients, about 50% of mutations (14 patients) were found in SDHD, whereas the others 
were found in VHL (7 patients), RET (5 patients), NF1, SDHB, and SDHC (1 patient each). 
Table 2 summarizes the characteristics of the Pheos, sPGLs, and HNPGLs in our 501 patients and 
the results of the genetic analysis, regardless of the family history and the association with other 
syndromic lesions. These data were analyzed to determine whether the clinical features of the 
Pheos/PGLs (secreting vs. nonsecreting, location, multiplicity, recurrence, tumor combinations) 
alone can provide indications on the gene that should be examined first. 
Pheos and sPGLs were present in 380 patients, HNPGLs in 106 patients, and the association of the 
two in 15 patients. 
Unilateral Pheos (n = 278) were associated with germ-line mutations in 20.7% of cases (8.6% VHL, 
5.8% RET, 3.2% NF1, 1.8% SDHB, and 1.4% SDHD, respectively). The mutation rate was over 
twice as high (56.2%) in patients with bilateral Pheos (n = 48), the mutations being found only in 
VHL (35.4%) or RET (20.8%) genes. 
sPGLs were diagnosed in 54 patients, and among these, 36 were affected by a single sPGL, four by 
multiple sPGLs, and 14 by the association of Pheo and sPGL. Single sPGLs were associated with a 
germ-line mutation in 41.7% of cases. These mutations were mostly found in the SDHB gene 
(27.8%) and, much less frequently, also in VHL, NF1, SDHC, and SDHD genes. Multiple sPGLs 
were found associated with germ-line mutations in 50% of cases, and all involved the SDHB gene. 
Most patients with HNPGLs only had a wild-type genotype [69 (65.1%) of the 106 patients with 
this type of tumor], but some had mutations involving one of the SDH genes (35 of 106, 33.0%) or, 
in two cases, VHL. There was no evidence of RET or NF1 mutations in this group. 
All 15 patients presenting with both a Pheo/sPGL and a HNPGL were affected by a germ-line 
mutation: 12 (80.0%) of the SDHD, one (6.7%) of the SDHB, and two (13.3%) of the VHL gene. 
The vast majority of the 150 mutations diagnosed by genetic analysis (as mentioned above, in 11 
patients NF1 was diagnosed clinically, as generally accepted) were missense (68.7%) or nonsense 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
(21.3%) mutations, although we also found frameshifts (4.0%), splicing alterations (4.7%), and two 
cases of genomic rearrangement (1.3%) both involving total deletion of the SDHD gene. 
Table 3 shows data on the 25 patients (5.0% of the population) with malignant disease. Over half 
(16 of 25, 64.0%) had wild-type genotypes. Malignancy rate ranged from 1.9% in HNPGLs to 4.9% 
in Pheos and 15.0% in sPGLs (P = 0.008). Secreting tumors were more likely to be associated with 
malignant disease than nonsecreting tumors (5.8 vs. 1.9%; P = 0.027). It is noteworthy that 20.8% 
(5 of 24) of the patients with SDHB mutations had malignant tumors, as compared with less than 
5% of those with mutations involving SDHD (2 of 47; 4.3%) or VHL (2 of 48; 4.2%). No malignant 
forms were observed in patients presenting germ-line mutations of the RET, NF1, or SDHC genes. 
Discussion 
The paper published in 2002 by Neumann et al. (6) raised interest about the percentage of 
hereditary PHEO/sPGLs, which they estimated around 24% in a group of patients classified as 
apparently sporadic. 
A more recent study of a large cohort of 314 French patients (8), again all with functional tumors, 
revealed hereditary disease in 86 (27.4%) cases (including 13 with phenotypically diagnosed NF1). 
However, the rate of inherited tumors in the subgroup with apparently sporadic presentations was 
only 11.6%. 
These different results might depend not only on the geographic origins of the series but also on the 
criteria of patient selection and classification. These latter can be particularly difficult for patients 
affected by Pheo/PGL, especially after the discovery of the PGL syndromes that increase the 
variability of the clinical presentation (11, 12, 13, 14, 15, 16, 17) and the mode of genetic 
transmission (18, 19). 
In the present study, which included patients with both functioning (Pheos/sPGLs) and 
nonfunctioning (HNPGLs) PGLs, we tried to classify each patient as accurately as possible, 
according to the two factors that can be assessed before the genetic analysis: family history and 
overall clinical picture. 
Eliciting a family history for these tumors can be difficult. False-negative findings can be caused by 
gaps and errors in the patient’s knowledge of his/her relatives’ medical histories, the presence of 
inherited syndromes with relatively low penetrance (e.g. PGL-4 syndrome) (14, 15, 16, 17), or the 
confounding effects of maternal imprinting, which is a feature of the PGL-1 syndrome (19). 
Nonetheless, a careful family history is of great importance in these patients because it can, when 
positive, address the genetic analysis to a specific gene or even to a specific mutation. In our series, 
57 patients had a positive family history, and among them, 30 belonged to families where a relative 
had already been diagnosed with a syndromic disease, letting us search for mutations in the 
correspondent gene. In the others, where a syndromic disease had still to be diagnosed, we had to 
rely exclusively on clinical presentation. In this group, patients with multiple or recurrent tumors 
were all mutation carriers. 
On a whole, 52 of 57 patients (91.2%) of this subgroup were mutation carriers. 
The fact that the remaining five patients were wild-type at genetic screening suggests that other 
susceptibility genes for Pheo/PGL might indeed exist (20, 21). Of note, each of these five patients 
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was affected by a single adrenal Pheo. Whether this group represents a phenotypic cluster of a 
mutated, still unknown, susceptibility gene remains to be established. 
Even when the family history was negative, the association of Pheo/PGL with a syndromic lesion 
was the strongest predictor of hereditary disease; in fact, all 57 patients presenting with this clinical 
picture were found to have a hereditary Pheo/PGL. 
In our series, 19 (38.8%) of the 49 patients presenting with multiple or recurrent Pheos/PGLs, a 
negative family history, and no syndromic lesions were mutation carriers. Therefore, tumor 
multiplicity and recurrence by itself should be considered a predictor of hereditary disease. Of note, 
bilateral Pheos were hereditary in more than 50% of patients and exclusively associated with 
mutations in VHL or RET. In these patients, the chemical phenotype of the tumors (adrenergic vs. 
noradrenergic) can offer an indication of the gene that should be tested first (22). 
Lastly, in the group with a negative family history, no syndromic lesions and single Pheo/PGL (the 
patients with tumors generally classified as “truly sporadic”) germ-line mutations were found in 40 
(11.6%) of the 345 patients. When Pheos/sPGLs and HNPGLs were considered separately, the 
correspondent mutation frequencies were, respectively, 10.8% (29 of 268), a percentage similar to 
that of the French study (8), and 14.3% (11 of 77), a frequency that is between those observed in 
similar but smaller cohorts in northern Spain (22.2%) (23) and in France (6.0%) (24). Overall, 
24.5% of patients with a negative family history were mutation carriers, a percentage close to that 
reported by Neumann et al. (6). 
Our study shows that the frequency of hereditary Pheo/PGL can vary widely, ranging from 11 to 
100% depending on the criteria used for patient selection. 
In addition to family history, the clinical picture can be of great help in planning the genetic 
analysis. 
In fact, the results of our genetic study demonstrate that type, number, and variable associations of 
Pheo/PGL can reliably predict which gene or genes are worth being screened, as shown in Fig. 2. 
It is interesting to note that, in our study, HNPGLs have been found, either isolated (two patients) or 
associated to Pheo/sPGL (two patients), in VHL mutation carriers. This finding indicates that in 
patients affected by HNPGLs, genetic analysis should not be limited to the SDHx genes but 
extended to VHL when SDHx genes are wild-type. Moreover, this clinical finding indirectly 
supports the hypothesis of a common pathogenesis, namely activation of the hypoxia-linked 
pathway, in VHL and SDHx-linked Pheo/PGL (25). 
Additional clinical guides to genetic analysis are age at Pheo/PGL presentation and malignancy. In 
our study, young age and metastatic disease are both predictors of SDHB mutation, in agreement 
with other studies (8, 16, 26, 27, 28). 
Age at presentation also proved to be another predictor of the presence of germ-line mutations in 
patients with clinically sporadic tumors (Fig. 1). In the subgroup of patients with secreting tumors, 
genetic forms are most likely when presentation occurs during the second decade of life. Later onset 
is associated with much lower mutation rates (less than 5% in the fifth decade). 
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Conversely, in the subgroup of patients with clinically sporadic HNPGLs, the frequency of germ-
line mutations is highest in the third decade and still remains high (above 20%) in the fifth decade. 
These data suggest that genetic testing should be performed in all young patients with Pheos/sPGLs, 
even when the tumor appears to be sporadic. Patients with clinically sporadic tumors that occur 
after the age of 50, regardless of their functionality, might be excluded from genetic testing because 
the frequency of mutations in these groups is around 5%. 
Nonetheless, it is worth mentioning that among the 29 mutation carriers older than 50 yr, 14 
(48.3%) had a negative family history and were, therefore, index cases who gave indications for 
genetic screening of their families. 
Our study confirms that malignancy is mostly linked to SDHB mutations. Nevertheless, it must be 
pointed out that other genes may be involved, although to a much lesser extent. 
As regards the type of mutations, we found (as reported in Table 3) that the vast majority of those 
involving VHL and RET were missense, as expected (1, 29, 30, 31, 32), and the same was true for 
the SDHB mutations. In contrast, SDHD and SDHC mutations were mostly of the nonsense type. 
Genomic rearrangements were found in only 1.2% (2 of 160) of the patients who were wild-type for 
all genes in sequencing studies. Although we limited the search for genomic rearrangements to 
patients under the age of 50 (the group that includes the vast majority of patients with germ-line 
mutations), such a low frequency suggests to us that this analysis is not worthwhile on a routine 
basis. 
In conclusion, we evaluated a large cohort of Italian patients with Pheos/PGLs. An accurate family 
history and an extensive clinical evaluation permitted us to separate our patients into different 
groups and to establish the correspondent incidences of mutations in the known susceptibility 
genes. 
The relative frequency of the different mutations permitted us to construct a comprehensive flow 
chart (Fig. 2) that, for the first time, takes into consideration not only patients with Pheos /sPGLs 
but also those with HNPGLs. This flow chart, which is based on the patient’s family history and 
clinical presentation, may represent a guide for the gene analysis strategy. 
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View LargerDownload Figure PowerPoint Slide 
Fig. 1. Percentage incidence of mutations per decades of ages in patients with clinically sporadic 
secreting tumors (Pheos and sPGLs) (open circles) and patients with clinically sporadic 
nonsecreting tumors (HNPGLs) (closed squares). 
View LargerDownload Figure PowerPoint Slide 
Fig. 2. Flow chart suggested for genetic analysis in patients affected by Pheos or PGLs. The genes 
reported in the boxes are those more likely to be found mutated according to clinical picture. MTC, 
Medullary thyroid carcinoma; HMGB, hemangioblastomas; CC, cancer/cysts. 
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TABLE 1. Classification of patients according to family history and clinical presentation 
Clinical presentation 
Positive family 
history 
Mutation 
frequency 
Negative family 
history 
Mutation 
frequency 
No. of females 38  250  
No. of males 19  194  
Mean age (yr) 39.1  45.7  
Age range (yr) 9–89  5–93  
Associated syndromic 
lesions 
 16/16 (100.0%)  50/50 (100.0%) 
VHL     9  23  
MEN2     6  17  
NF1     1  10  
Multiple/recurrent 
Pheo/PGL 
 27/27 (100.0%)  19/49 (38.8%) 
Pheos/sPGL     5  35  
HNPGL     14  10  
Pheos/sPGL + HNPGL     8  4  
Single Pheo/PGL  9/14 (64.3%)  40/345 (11.6%) 
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Clinical presentation 
Positive family 
history 
Mutation 
frequency 
Negative family 
history 
Mutation 
frequency 
Pheo     9  233  
sPGL     1  35  
HNPGL     4  77  
Total 57 52/57 (91.2%) 109 109/444 
(24.5%) 
 
TABLE 2. Genotype profile of the different clinical 
presentations as defined by the number and type of 
Pheos and/or PGLs 
 
TABLE 2. Genotype profile of the different clinical presentations as defined by the number and 
type of Pheos and/or PGLs 
 
Mutation 
      
 
VHL RET NF1
1
 SDHB SDHC SDHD 
Wild-
type     
Patient features        
     
All (n = 501)     48 
(9.6%) 
27 
(5.4%) 
11 
(2.2%) 
24 
(4.8%) 
4 
(0.8%) 
47 
(9.3%) 
340 
(67.9%)      
Males (n = 213)     23 9 5 11 1 19 145 
     
Females (n = 288)     25 18 6 13 3 28 195 
     
Age at diagnosis (yr)           
     
Mean         30.0 36.5 42.3 28.7 43.0 39.7 49.6 
     
Range         9–67 18–65 29–62 9–55 16–73 14–69 5–93 
     
Presentation        
     
Secreting tumors only 
(n = 380)     
44 
(12.0%) 
27 
(7.0%) 
11 
(2.9%) 
19 
(5.0%) 
1 
(0.3%) 
7 (1.8%) 271 
(71.0%)      
Unilateral Pheo (n = 
278)         
24 16 9 5  4 220 
     
Bilateral Pheo (n = 48)         17 10     21 
     
Single sPGL (n = 36)         2  1 10 1 1 21 
     
Multiple sPGL (n = 4)            2   2 
     
Pheos + sPGL (n = 14)         1 1 1 2  2 7 
     
Nonsecreting tumors 
only (n = 106)     
2 (1.9%)   4 
(3.8%) 
3 
(2.8%) 
28 
(26.4%) 
69 
(65.1%)      
Single HNPGL (n = 
96)         
2   3 3 21 67 
     
Multiple HNPGLs (n 
= 10)         
   1  7 2 
     
Secreting and        
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Mutation 
      
 
VHL RET NF1
1
 SDHB SDHC SDHD 
Wild-
type     
nonsecreting tumors     
Pheo/sPGL + HNPGL 
(n = 15)         
2 
(13.3%) 
0 (0%) 0 (0%) 1 
(6.7%) 
0 (0%) 12 
(80.0%) 
0 (0%) 
     
1
The presence of NF1 mutations was deduced on the basis of phenotype. 
 
TABLE 3. Clinical characteristics, phenotype, and gene mutations in 
25 patients affected by malignant Pheo/PGL 
 
TABLE 3. Clinical characteristics, phenotype, and gene mutations in 25 patients affected by 
malignant Pheo/PGL 
 
WT VHL SDHB SDHD Total % Malignancy 
Gender       
Females     10 1 2 2 15  
Males     6 1 3 0 10  
Mean age at diagnosis (yr) 48.1 28.0 20.8 36.0   
Phenotype       
HNPGL     1 0 0 1 2 1.9 (2/106) 
Pheo           
Monolateral         10 1 1 1 13 4.9 (16/326) 
Bilateral         3 0 0 0 3  
Extraadrenal PGL           
Single         2 0 2 0 4 15.0 (6/40) 
Multiple         0 0 2 0 2  
Intra- + extraadrenal     0 0 0 0 0 0 (0/14) 
Secreting + nonsecreting PGL     0 1 0 0 1 6.6 (1/15) 
Total 16 2 5 2 25 5.0 (25/501) 
WT, Wild type. 
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